Table 2 Geometric means of responses and fold reduction in paired samples of Omicron responder subsets.
Paired responders in sample cohort (n; [% of total n per vaccination scheme]) | GMT (95% CI) of paired responders across indicated variants | |||
|---|---|---|---|---|
B.1 | Beta B.1.351 | Delta B.1.617.2 | Omicron BA.1 | |
One-dose Ad26.CoV2.S * (1; [4.4]) | na | na | na | na |
Two-dose AZD1222 (14; [56.0]) | 155.80 (96.60–251.20) | 40.98 (23.66–70.97) | 83.52 (49.68–140.40) | 14.39 (8.92–23.23) |
First dose AZD1222, second dose BNT162b2 (21; [84.0]) | 791.90 (558.90–1122.00) | 132.0 (87.94–198.00) | 469.50 (316.00–697.50) | 49.72 (34.00–72.71) |
First dose AZD1222, second dose mRNA-1273 (21; [87.5]) | 1098.00 (793.80–1518.00) | 284.20 (183.20–440.90) | 760.70 (513.60–1127.00) | 78.68 (54.36–113.90) |
Two-dose mRNA-1273 (24; [100.0]) | 453.80 (351.2–586.4) | 85.48 (55.45–131.80) | 393.50 (284.4–544.4) | 29.50 (21.58–40.33) |
Two-dose BNT162b2 T1 (11; [47.8]) ** | 406.80 (300.90–550.00) | 54.41 (32.19–91.99) | 371.00 (243.30–565.50) | 18.21 (11.83–28.03) |
Two-dose BNT162b2 T2 (13; [56.2]) ** | 98.77 (68.41–142.60) | 33.07 (21.25–51.45) | 82.63 (53.60–127.4) | 14.22 (9.74–20.75) |
Paired responders in sample cohort (n; [% of total n per vaccination scheme]) | Fold reduction in GMT of paired responders across indicated variants | |||
|---|---|---|---|---|
B.1 | Beta B.1.351 | Delta B.1.617.2 | Omicron BA.1 | |
One-dose Ad26.CoV2.S * (1; [4.4]) | – | na | na | na |
Two-dose AZD1222 (14; [56.0]) | – | 3.80 | 1.87 | 10.83 |
First dose AZD1222, second dose BNT162b2 (21; [84.0]) | – | 6.00 | 1.69 | 15.93 |
First dose AZD1222, second dose mRNA-1273 (21; [87.5]) | – | 3.86 | 1.44 | 13.96 |
Two-dose mRNA-1273 (24; [100.0]) | – | 5.31 | 1.15 | 15.38 |
Two-dose BNT162b2 T1 (11; [47.8]) ** | – | 7.48 | 1.10 | 22.34 |
Two-dose BNT162b2 T2 (13; [56.2]) ** | – | 2.99 | 1.20 | 6.95 |
